The multifaceted role of CD146/MCAM in the promotion of melanoma progression

Cancer Cell International

Huan Wang³  Yang Song²  Ce-Wen Guan³  Xing Lei¹ 

[1]Department of Orthopedic Surgery, Linyi People’s Hospital, Linyi 276000, China

[2]Department of Orthopedic Surgery, the Second Affiliated Hospital, Harbin Medical University, Harbin 150001, China

[3]Department of Orthopedic Surgery, the First Affiliated Hospital, Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin 150001, China

关键词: Angiogenesis;    Metastasis;    Mechanism;    Structure;    Melanoma;    CD146/MCAM;   

Others  :  1138653
DOI  :  10.1186/s12935-014-0147-z

 received in 2014-11-20, accepted in 2014-12-17,  发布年份 2015

【 摘 要 】

Human malignant melanoma is a common primary malignant cutaneous tumour derived from transformed epidermal melanocytes. Patients with melanoma have a high rate of mortality due to resistance to chemotherapeutic drugs, a major obstacle to a successful treatment. Several reports have suggested that CD146 plays an important role as a signalling molecule in human melanoma. This role includes CD146 as a participant in inflammation, differentiation, adhesion, tumourigenicity, metastasis, invasion and angiogenesis among other processes, which suggests that this molecule promotes the progression of human melanoma as a multifaceted regulator. In this article, we explore the effects and corresponding mechanisms with respect to the role of CD146/MUC18 in the promotion of human melanoma progression. Collectively, the studies indicated that targeting CD146, because it is a suitable marker of poor patient outcome, might be useful in the design of future strategies for the prevention and treatment of human melanoma.

【 授权许可】

   
2015 Lei et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Leiter U, Eigentler T, Garbe C: Epidemiology of skin cancer. Adv Exp Med Bio 2014, 810:120-140.
• [2]Mayer JE, Swetter SM, Fu T, Geller AC: Screening, early detection, education, and trends for melanoma: current status (2007–2013) and future directions: part I. epidemiology, high-risk groups, clinical strategies, and diagnostic technology. J Am Acad Dermatol 2014, 4:599. e591-599 e512; quiz 610, 599 e512
• [3]DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014, 4:252-271.
• [4]Wang Z, Yan X: CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013, 2:150-162.
• [5]Wu GJ, Fu P, Wang SW, Wu MW: Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model. Mol Cancer Res 2008, 11:1666-1677.
• [6]Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, Stella A, Jensen-Jarolim E, Holler C, Wacheck V, Pehamberger H, Valent P: Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One 2014, 1:e84417.
• [7]Ishikawa T, Wondimu Z, Oikawa Y, Gentilcore G, Kiessling R, Egyhazi Brage S, Hansson J, Patarroyo M: Laminins 411 and 421 differentially promote tumor cell migration via alpha6beta1 integrin and MCAM (CD146). Matrix Biol 2014, 38:69-83.
• [8]Ishikawa T, Wondimu Z, Oikawa Y, Ingerpuu S, Virtanen I, Patarroyo M: Monoclonal antibodies to human laminin alpha4 chain globular domain inhibit tumor cell adhesion and migration on laminins 411 and 421, and binding of alpha6beta1 integrin and MCAM to alpha4-laminins. Matrix Biol 2014, 36:5-14.
• [9]Ordonez NG: Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol 2014, 2:191-205.
• [10]Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB: Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001, 1:17-31.
• [11]Zhang Y, Zheng C, Zhang J, Yang D, Feng J, Lu D, Yan X: Generation and characterization of a panel of monoclonal antibodies against Distinct Epitopes of Human CD146. Hybridoma 2008, 5:345-352.
• [12]Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D, Yang D, Feng J, Yan X: Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 2009, 11:2163-2172.
• [13]Luo Y, Zheng C, Zhang J, Lu D, Zhuang J, Xing S, Feng J, Yang D, Yan X: Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 2012, 3:306-321.
• [14]Guezguez B, Vigneron P, Lamerant N, Kieda C, Jaffredo T, Dunon D: Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J Immunol 2007, 10:6673-6685.
• [15]Boneberg EM, Illges H, Legler DF, Furstenberger G: Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. Microvasc Res 2009, 3:325-331.
• [16]Chen W, Cao G, Zhang S-L: Is CD146 pivotal in neoplasm invasion and blastocyst embedding? Med Hypotheses 2011, 3:378-380.
• [17]Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG: Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science 2008, 5874:365-369.
• [18]Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, Zeni B, Griso C, Pegoraro C, Zannoni M, Gariboldi M, Balladore E, Mezzanzanica D, Canevari S, Barbareschi M: M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006, 8:1920-1926.
• [19]Witze ES, Connacher MK, Houel S, Schwartz MP, Morphew MK, Reid L, Sacks DB, Anseth KS, Ahn NG: Wnt5a directs polarized calcium gradients by recruiting cortical endoplasmic reticulum to the cell trailing edge. Dev Cell 2013, 6:645-657.
• [20]Mladinich KM, Huttenlocher A: WRAMPing up calcium in migrating cells by localized ER transport. Dev Cell 2013, 6:560-561.
• [21]Schwartz MP, Rogers RE, Singh SP, Lee JY, Loveland SG, Koepsel JT, Witze ES, Montanez-Sauri SI, Sung KE, Tokuda EY, Sharma Y, Everhart LM, Nguyen EH, Zaman MH, Beebe DJ, Ahn NG, Murphy WL, Anseth KS: A quantitative comparison of human HT-1080 fibrosarcoma cells and primary human dermal fibroblasts identifies a 3D migration mechanism with properties unique to the transformed phenotype. PLoS One 2013, 12:e81689.
• [22]Maru GB, Gandhi K, Ramchandani A, Kumar G: The role of inflammation in skin cancer. Adv Exp Med Biol 2014, 816:437-469.
• [23]Coffelt SB, de Visser KE: Cancer: inflammation lights the way to metastasis. Nature 2014, 7490:48-49.
• [24]Xing S, Luo Y, Liu Z, Bu P, Duan H, Liu D, Wang P, Yang J, Song L, Feng J, Yang D, Qin Z, Yan X: Targeting endothelial CD146 attenuates colitis and prevents colitis-associated carcinogenesis. Am J Pathol 2014, 5:1604-1616.
• [25]Ueda M, Fujisawa T, Ono M, Hara ES, Pham HT, Nakajima R, Sonoyama W, Kuboki T: A short-term treatment with tumor necrosis factor-alpha enhances stem cell phenotype of human dental pulp cells. Stem Cell Res Ther 2014, 1:31. BioMed Central Full Text
• [26]Yeremenko N, Noordenbos T, Cantaert T, van Tok M, van de Sande M, Canete JD, Tak PP, Baeten D: Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis. Arthritis Rheum 2013, 1:174-185.
• [27]Wu Q, Case SR, Minor MN, Jiang D, Martin RJ, Bowler RP, Wang J, Hartney J, Karimpour-Fard A, Chu HW: A novel function of MUC18: amplification of lung inflammation during bacterial infection. Am J Pathol 2013, 3:819-827.
• [28]Larochelle C, Cayrol R, Kebir H, Alvarez JI, Lecuyer MA, Ifergan I, Viel E, Bourbonniere L, Beauseigle D, Terouz S, Hachehouche L, Gendron S, Poirier J, Jobin C, Duquette P, Flanagan K, Yednock T, Arbour N, Prat A: Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. Brain 2012, 10:2906-2924.
• [29]Duan H, Xing S, Luo Y, Feng L, Gramaglia I, Zhang Y, Lu D, Zeng Q, Fan K, Feng J, Yang D, Qin Z, Couraud PO, Romero IA, Weksler B, Yan X: Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. Sci Rep 2013, 3:1687-1698.
• [30]Schneider SL, Ross AL, Grichnik JM. Do inflammatory pathways drive melanomagenesis? Exp Dermatol. 2014, doi: 10.1111/exd.12502.
• [31]Hoek KS, Goding CR: Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010, 6:746-759.
• [32]Russell KC, Tucker HA, Bunnell BA, Andreeff M, Schober W, Gaynor AS, Strickler KL, Lin S, Lacey MR, O’Connor KC: Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Eng Part A 2013, 19:2253-2266.
• [33]Stopp S, Bornhauser M, Ugarte F, Wobus M, Kuhn M, Brenner S, Thieme S: Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. Haematologica 2013, 4:505-513.
• [34]Maijenburg MW, Kleijer M, Vermeul K, Mul EP, van Alphen FP, van der Schoot CE, Voermans C: The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haematologica 2012, 2:179-183.
• [35]Magnoni C, Giudice S, Pellacani G, Bertazzoni G, Longo C, Veratti E, Morini D, Benassi L, Vaschieri C, Azzoni P, De Pol A, Seidenari S, Tomasi A, Pollio A, Ponti G: Stem cell properties in cell cultures from different stage of melanoma progression. Appl Immunohistochem Mol Morphol 2014, 3:171-181.
• [36]Lugassy C, Wadehra M, Li X, Corselli M, Akhavan D, Binder SW, Peault B, Cochran AJ, Mischel PS, Kleinman HK, Barnhill RL: Pilot study on “pericytic mimicry” and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenviron 2013, 1:19-29.
• [37]Lapan AD, Rozkalne A, Gussoni E: Human fetal skeletal muscle contains a myogenic side population that expresses the melanoma cell-adhesion molecule. Hum Mol Genet 2012, 16:3668-3680.
• [38]Lapan AD, Gussoni E: Isolation and characterization of human fetal myoblasts. Methods Mol Biol 2012, 798:3-19.
• [39]Suriano R, Rajoria S, L George A, Geliebter J, Wallack M, Tiwari RK: Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines. J Cancer Educ 2013, 5:371-382.
• [40]Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, Bar-Eli M: Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002, 17:5106-5114.
• [41]Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, Kamiya T, Melnikova VO, Song R, Friedman R, Alani RM, Bar-Eli M: Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res 2011, 10:3494-3504.
• [42]Schlagbauer-Wadl H, Jansen B, Muller M, Polterauer P, Wolff K, Eichler HG, Pehamberger H, Konak E, Johnson JP: Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer 1999, 6:951-955.
• [43]Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X: CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A 2012, 4:1127-1132.
• [44]Zeng G, Cai S, Liu Y, Wu GJ: METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene 2012, 1:229-238.
• [45]Todorovic V, Sersa G, Cemazar M: Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28. Cancer Gene Ther 2013, 3:208-210.
• [46]Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M: Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 2003, 44:6891-6899.
• [47]Wu G-J, Wu M-WH, Wang C, Liu Y: Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol 2011, 4:1504-1512.
• [48]Watson-Hurst K, Becker D: The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 2006, 10:1375-1382.
• [49]Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, Feng J, Yang D, Yan X: CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012, 11:2330-2339.
• [50]Zeng Q, Wu Z, Duan H, Jiang X, Tu T, Lu D, Luo Y, Wang P, Song L, Feng J, Yang D, Yan X: Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell 2014, 6:445-456.
• [51]Ma X, Liu J, Wu J, Yan X, Wu P, Liu Y, Li S, Tian Y, Cao Y, Chen G, Meng L, Xu G, Wang S, Lu Y, Ma D, Zhou J: Synergistic killing effect between vorinostat and target of CD146 in malignant cells. Clin Cancer Res 2010, 21:5165-5176.
• [52]Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C: Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 2010, 7:1877-1886.
• [53]Leslie MC, Zhao YJ, Lachman LB, Hwu P, Bar-Eli M: Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther 2007, 4:316-323.
• [54]Estecha A, Sanchez-Martin L, Puig-Kroger A, Bartolome RA, Teixido J, Samaniego R, Sanchez-Mateos P: Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci 2009, 122:3492-3501.
• [55]Melnikova VO, Bar-Eli M: Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006, 5:395-405.
• [56]Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997, 11:2295-2303.
• [57]Wu G-J, Peng Q, Fu P, Wang S-W, Chiang C-F, Dillehay DL, Wu M-WH: Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 2004, 2:201-213.
• [58]Wang HF, Chen H, Ma MW, Wang JA, Tang TT, Ni LS, Yu JL, Li YZ, Bai BX: miR-573 regulates melanoma progression by targeting the melanoma cell adhesion molecule. Oncol Rep 2013, 1:520-526.
• [59]Chen R, Dong Y, Xie X, Chen J, Gao D, Liu Y, Ren Z, Cui J: Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. Int J Clin Exp Pathol 2014, 5:2527-2535.
• [60]Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, Petersson F, Price JE, Schroit A, Prieto VG, Hung MC, Bar-Eli M: Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates Melanoma Cell Adhesion Molecule (MCAM/MUC18) Expression and Melanoma Metastasis. J Biol Chem 2009, 42:28845-28855.
• [61]Hung PF, Hong TM, Hsu YC, Chen HY, Chang YL, Wu CT, Chang GC, Jou YS, Pan SH, Yang PC: The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma. PLoS One 2013, 4:e61664.
• [62]Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M: Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008, 21:9078-9086.
• [63]Krifka S, Spagnuolo G, Schmalz G, Schweikl H: A review of adaptive mechanisms in cell responses towards oxidative stress caused by dental resin monomers. Biomaterials 2013, 19:4555-4563.
• [64]Ashida N, SenBanerjee S, Kodama S, Foo SY, Coggins M, Spencer JA, Zamiri P, Shen D, Li L, Sciuto T, Dvorak A, Gerszten RE, Lin CP, Karin M, Rosenzweig A: IKKβ regulates essential functions of the vascular endothelium through kinase-dependent and -independent pathways. Nat Commun 2011, 2:318-327.
• [65]Lorentzen A, Bamber J, Sadok A, Elson-Schwab I, Marshall CJ: An ezrin-rich, rigid uropod-like structure directs movement of amoeboid blebbing cells. J Cell Sci 2011, 124:1256-1267.
• [66]Punchihewa C, Ferreira AM, Cassell R, Rodrigues P, Fujii N: Sequence requirement and subtype specificity in the high-affinity interaction between human frizzled and dishevelled proteins. Protein Sci 2009, 5:994-1002.
• [67]Jackson LP, Lewis M, Kent HM, Edeling MA, Evans PR, Duden R, Owen DJ: Molecular basis for recognition of dilysine trafficking motifs by COPI. Dev Cell 2012, 6:1255-1262.
• [68]Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu D, Feng J, Yang D, Song L, Yan X: MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol 2013, 18:3689-3699.
• [69]Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti MD, Berenguer C, Lamy E, Vely F, Pisano P, Ouafik L, Sabatier F, Sampol J, Bardin N, Dignat-George F, Blot-Chabaud M: Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 2010, 18:3843-3851.
• [70]Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M: Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem 2013, 13:8991-9000.
• [71]Kebir A, Harhouri K, Guillet B, Liu JW, Foucault-Bertaud A, Lamy E, Kaspi E, Elganfoud N, Vely F, Sabatier F, Sampol J, Pisano P, Kruithof EKO, Bardin N, Dignat-George F, Blot-Chabaud M: CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells In Vitro and In Vivo. Circ Res 2010, 1:66-75.
• [72]Karst AM, Gao K, Nelson CC, Li G: Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 2009, 2:494-501.
• [73]Wani AA, Jafarnejad SM, Zhou J, Li G: Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/interleukin-6 signaling pathway. Oncogene 2011, 24:2778-2788.
• [74]Zhuang J, Jiang T, Lu D, Luo Y, Zheng C, Feng J, Yang D, Chen C, Yan X: NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction. Free Radic Biol Med 2010, 2:227-236.
• [75]Bu P, Zhuang J, Feng J, Yang D, Shen X, Yan X: Visualization of CD146 dimerization and its regulation in living cells. Biochim Biophys Acta Mol Cell Res 2007, 4:513-520.
• [76]Infante T, Cesario E, Gallo M, Fazioli F, De Chiara A, Tutucci C, Apice G, de Nigris F: Ex vivo behaviour of human bone tumor endothelial cells. Cancers (Basel) 2013, 2:404-417.
• [77]Kucerova L, Zmajkovic J, Toro L, Skolekova S, Demkova L, Matuskova M. Tumor-driven molecular changes in human mesenchymal stromal cells. Cancer Microenviron. 2014, doi:10.1007/s12307-014-0151-9.
• [78]Linnskog R, Jonsson G, Axelsson L, Prasad CP, Andersson T: Interleukin-6 drives melanoma cell motility through p38alpha-MAPK-dependent up-regulation of WNT5A expression. Mol Oncol 2014, 8:1365-1378.
• [79]Rapanotti MC, Ricozzi I, Campione E, Orlandi A, Bianchi L: Blood MUC-18/MCAM expression in patients with melanoma: a suitable marker of poor outcome. Br J Dermatol 2013, 1:221-222.
• [80]Ilie M, Long E, Hofman V, Selva E, Bonnetaud C, Boyer J, Venissac N, Sanfiorenzo C, Ferrua B, Marquette CH, Mouroux J, Hofman P: Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer 2014, 5:1236-1243.
• [81]Okazaki Y, Nagai H, Chew SH, Li J, Funahashi S, Tsujimura T, Toyokuni S: CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma. Cancer Sci 2013, 8:989-995.
• [82]Ren X, Yan T, Zhang Y, Wu D, Ma H, Li H, Du B, Wei Q: Nanosheet Au/Co3O4-based ultrasensitive nonenzymatic immunosensor for melanoma adhesion molecule antigen. Biosens Bioelectron 2014, 58:345-350.